Searched for
BIOCON INVESTMENT POTENTIAL
From Adani Green to Tata Tech: 50 companies swing back to profit in Q4 despite market turmoilIndian companies show strong recovery. Over 50 firms moved from losses to profits in the March quarter. This turnaround happened despite ma...- Industry expects policy continuity, faster execution under Shivakumar in KarnatakaExecutives from the technology, semiconductor and digital economy ecosystem said Karnataka’s long-standing strengths in talent, research an...
- Bernstein initiates coverage on 6 pharma stocks, cites 3 major tailwinds for healthcare sectorBernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future g...
- Biocon shifts focus to margins, capacity utilisation after expansion phaseBiocon is shifting its strategy to focus on capacity utilization, margin expansion, and improved returns after significant investments in g...
- Syngene shares zoom 17% even as firm’s Q4 net profit drops 19% YoY. What's driving the surge?Syngene shares surged despite a 19% YoY decline in Q4FY26 net profit to Rs 148 crore, as earnings rebounded sharply from Rs 15 crore in the...
- With sights on huge gains, Biocon to scale up AI focusBiopharma major Biocon is significantly scaling up its adoption of artificial intelligence across its operations, from R&D to manufacturing...
- Biocon shares in focus ahead of board meeting, fundraising plansBiocon shares: Biocon’s Board will meet on Saturday, December 6, 2025, to decide on key proposals that could shape its growth and sharehold...
- Stocks in news: ONGC, NTPC, SBI Life, Manappuram Finance, BioconNTPC along with its arm NTPC Green Energy signed multiple MoUs with Madhya Pradesh government to invest over Rs 2 lakh crore in the state.
- Competition Commission of India penalises investment manager of Goldman Sachs AIF for failing to notify Biocon dealThe Competition Commission of India has imposed a Rs 40 lakh penalty on Goldman Sachs AIMPL for not notifying the regulator about a deal in...
- Motilal Oswal Financial Services upgrades Biocon to Buy, target price Rs 430Motilal Oswal Financial Services has recommended a buy on Biocon, targeting a price of Rs 430. The company, a leader in the pharmaceuticals...
- Stocks to buy today: CLSA upgrades ONGC; Citi initiates buy on Hyundai Motor IndiaCLSA has upgraded ONGC to "High Conviction Overweight-PF," citing multiple production and realization triggers, alongside attractive valuat...
- Biocon Biologics may raise additional equity of $300 million in FY24 to pare debtBiocon Biologics plans to raise a further $300m by the end of FY24 in order to reduce its net debt, which peaked at $1.9bn in December 2022...
- Can Serum deal provide a booster dose to Biocon's target price?The Serum alliance would give Biocon Biologics' access to 100 million doses of vaccines per annum for 15 years with commercialisation right...
- Citigroup has buy on Biocon, target price Rs 360Biocon is the best Indian play on the global biosimilars opportunity, said Citigroup.
- Syngene's valuations are fair, investors need to invest in its growth story: Kiran Mazumdar-ShawIn an interview with ET Now, Kiran Mazumdar-Shaw, CMD, Biocon, talks about the Syngene IPO and the growth prospects involved.
- Buy Biocon: Gaurang Shah, Geojit BNP Paribas Financial ServicesWe did have a buy recommendation and our clients would still be holding their position and the entire midcap domestic pharma play is going ...
- Biocon seals Rs 1,550 cr pact with PfizerThe agreement includes the commercialisation of Biocon’s biosimilar versions of insulin and insulin analog products: recombinant human insu...
- Biocon Q4 profit zooms to Rs 81 croreBiotechnology major Biocon's net profit for the fourth quarter rose sharply after revenues increased and a forex loss of Rs 41.4 crore had ...
- Biocon LTD signs MoU with Malaysian-based BiotechCorpBiocon Limited today signed an MoU with Malaysia's Biotechnology Corporation (BiotechCorp) to explore collaboration and potential investmen...
- Biocon to sell enzymes biz for $115 mnWe were investing already in the biopharma segment which can deliver more than enzymes business, says Biocon CMD.
Load More
